Merck & Co Inc (6MK) Stock Price & News

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia

About Merck & Co Inc

CEORobert M Davis

Employees74K

FoundedJan 1, 1891

Headquarters-

SectorPharmaceutical industry

Websitemerck.com

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	17.28B	16.40B	16.29B	16.61B
Cost of goods sold	3.74B	4.30B	3.88B	4.13B
Cost of revenue	3.74B	4.30B	3.88B	4.13B
Research and development expenses	4.00B	4.00B	3.56B	9.74B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2.48B	2.73B	2.57B	2.78B
Operating expense	6.48B	6.73B	6.12B	12.52B
Total operating expenses	10.23B	11.02B	10.00B	16.65B
Operating income	7.05B	5.38B	6.29B	-40.00M
Other non operating income	-	41.00M	42.00M	59.00M
EBT including unusual items	6.74B	3.42B	-3.53B	-683.00M
EBT excluding unusual items	6.76B	4.98B	5.85B	-508.00M
Income tax expense	958.00M	458.00M	709.00M	654.00M
Effective tax rate	14.20%	13.39%	-20.06%	-95.75%
Other operating expenses	-	-	-	-
Net income	5.78B	2.96B	-4.24B	-1.34B
Net profit margin	33.49%	18.07%	-26.03%	-8.04%
Earnings per share	2.58	2.04	-1.28	-0.13
Interest and investment income	96.00M	69.00M	35.00M	35.00M
Interest expense	-327.00M	-411.00M	-479.00M	-525.00M
Net interest expenses	-231.00M	-342.00M	-444.00M	-490.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	8.15B	6.79B	7.69B	1.43B
Gain or loss from assets sale	-	-	-	-

Ask anything